A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC).
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2015
At a glance
- Drugs Imetelstat (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Geron Corporation
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 05 Apr 2013 Data, including a subgroup analysis, will be presented at the American Association for Cancer Research Annual Meeting 2013, according to a Sarah Cannon Research Institute media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History